BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vranjkovic A, Deonarine F, Kaka S, Angel JB, Cooper CL, Crawley AM. Direct-Acting Antiviral Treatment of HCV Infection Does Not Resolve the Dysfunction of Circulating CD8+ T-Cells in Advanced Liver Disease. Front Immunol 2019;10:1926. [PMID: 31456810 DOI: 10.3389/fimmu.2019.01926] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Laguno M, Martínez-Rebollar M, Casanova M, de Lazzari E, González-Cordón A, Torres B, Inciarte A, Mora L, Ugarte A, Ambrosioni J, Blanco JL, Martínez E, Mallolas J. Long-term evolution in liver fibrosis and immune profile after direct-acting antivirals therapy in hepatitis C virus-human immunodeficiency virus co-infected patients. Clin Microbiol Infect 2021:S1198-743X(21)00479-1. [PMID: 34464735 DOI: 10.1016/j.cmi.2021.08.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Wu X, Roberto JB, Knupp A, Greninger AL, Truong CD, Hollingshead N, Kenerson HL, Tuefferd M, Chen A, Koelle DM, Horton H, Jerome KR, Polyak SJ, Yeung RS, Crispe IN. Response of Human Liver Tissue to Innate Immune Stimuli. Front Immunol 2022;13:811551. [PMID: 35355993 DOI: 10.3389/fimmu.2022.811551] [Reference Citation Analysis]
3 Duncan JD, Urbanowicz RA, Tarr AW, Ball JK. Hepatitis C Virus Vaccine: Challenges and Prospects. Vaccines (Basel) 2020;8:E90. [PMID: 32079254 DOI: 10.3390/vaccines8010090] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
4 Okwor CIA, Oh JS, Crawley AM, Cooper CL, Lee SH. Expression of Inhibitory Receptors on T and NK Cells Defines Immunological Phenotypes of HCV Patients with Advanced Liver Fibrosis. iScience 2020;23:101513. [PMID: 32920488 DOI: 10.1016/j.isci.2020.101513] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Medeiros T, Saraiva GN, Moraes LA, Gomes AC, Lacerda GS, Leite PE, Esberard EB, Andrade TG, Xavier AR, Quírico-Santos T, Rosário NF, Silva AA. Liver fibrosis improvement in chronic hepatitis C after direct acting-antivirals is accompanied by reduced profibrogenic biomarkers-a role for MMP-9/TIMP-1. Dig Liver Dis 2020;52:1170-7. [PMID: 32522433 DOI: 10.1016/j.dld.2020.05.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Ramadan HK, Badr G, Ramadan NK, Sayed A. Enhanced immune responses, PI3K/AKT and JAK/STAT signaling pathways following hepatitis C virus eradication by direct-acting antiviral therapy among Egyptian patients: a case control study. Pathog Dis 2021;79:ftab008. [PMID: 33524139 DOI: 10.1093/femspd/ftab008] [Reference Citation Analysis]
7 Weigand K, Peschel G, Grimm J, Luu K, Schacherer D, Wiest R, Müller M, Schwarz H, Buechler C. Soluble CD137 is a novel serum marker of liver cirrhosis in patients with hepatitis C and alcohol-associated disease etiology. Eur J Immunol 2021. [PMID: 34914098 DOI: 10.1002/eji.202149488] [Reference Citation Analysis]
8 Dash S, Aydin Y, Widmer KE, Nayak L. Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment. J Hepatocell Carcinoma 2020;7:45-76. [PMID: 32346535 DOI: 10.2147/JHC.S221187] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
9 Osuch S, Metzner KJ, Caraballo Cortés K. Reversal of T Cell Exhaustion in Chronic HCV Infection. Viruses 2020;12:E799. [PMID: 32722372 DOI: 10.3390/v12080799] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Auma AWN, Shive CL, Lange A, Damjanovska S, Kowal C, Zebrowski E, Pandiyan P, Wilson B, Kalayjian RC, Canaday DH, Anthony DD. Naïve CD4+ T Cell Lymphopenia and Apoptosis in Chronic Hepatitis C Virus Infection Is Driven by the CD31+ Subset and Is Partially Normalized in Direct-Acting Antiviral Treated Persons. Front Immunol 2021;12:641230. [PMID: 33912168 DOI: 10.3389/fimmu.2021.641230] [Reference Citation Analysis]
11 Cao S, Liu M, Sehrawat TS, Shah VH. Regulation and functional roles of chemokines in liver diseases. Nat Rev Gastroenterol Hepatol 2021;18:630-47. [PMID: 33976393 DOI: 10.1038/s41575-021-00444-2] [Reference Citation Analysis]
12 Farcomeni S, Moretti S, Fimiani C, Sulekova LF, Vescio F, Sernicola L, Maggiorella MT, Remoli AL, Picconi O, Mosca L, Esvan R, Biliotti E, Ciccozzi M, Sgarbanti M, Taliani G, Borsetti A. Short- and Long-Term Immunological Responses in Chronic HCV/HIV Co-Infected Compared to HCV Mono-Infected Patients after DAA Therapy. Pathogens 2021;10:1488. [PMID: 34832642 DOI: 10.3390/pathogens10111488] [Reference Citation Analysis]
13 Thakuri BKC, Zhang J, Zhao J, Nguyen LN, Nguyen LNT, Schank M, Khanal S, Dang X, Cao D, Lu Z, Wu XY, Jiang Y, El Gazzar M, Ning S, Wang L, Moorman JP, Yao ZQ. HCV-Associated Exosomes Upregulate RUNXOR and RUNX1 Expressions to Promote MDSC Expansion and Suppressive Functions through STAT3-miR124 Axis. Cells 2020;9:E2715. [PMID: 33353065 DOI: 10.3390/cells9122715] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
14 Rosário NF, Saraiva GDN, Medeiros T, Gandini M, Lacerda G, Leite PEC, Andrade TG, Azeredo EL, Xavier AR, Silva AA. Successful DAA therapy for chronic hepatitis C reduces HLA-DR on monocytes and circulating immune mediators: A long-term follow-up study. Immunol Lett 2020;228:15-23. [PMID: 32946919 DOI: 10.1016/j.imlet.2020.09.002] [Reference Citation Analysis]
15 Soliman SHA, Orlacchio A, Verginelli F. Viral Manipulation of the Host Epigenome as a Driver of Virus-Induced Oncogenesis. Microorganisms 2021;9:1179. [PMID: 34070716 DOI: 10.3390/microorganisms9061179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Datfar T, Doulberis M, Papaefthymiou A, Hines IN, Manzini G. Viral Hepatitis and Hepatocellular Carcinoma: State of the Art. Pathogens 2021;10:1366. [PMID: 34832522 DOI: 10.3390/pathogens10111366] [Reference Citation Analysis]
17 Leslie J, Geh D, Elsharkawy AM, Mann DA, Vacca M. Metabolic dysfunction and cancer in HCV: shared pathways and mutual interactions. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.01.029] [Reference Citation Analysis]
18 Nguyen LN, Nguyen LNT, Zhao J, Schank M, Dang X, Cao D, Khanal S, Thakuri BKC, Zhang J, Lu Z, Wu XY, El Gazzar M, Ning S, Wang L, Moorman JP, Yao ZQ. Immune Activation Induces Telomeric DNA Damage and Promotes Short-Lived Effector T Cell Differentiation in Chronic HCV Infection. Hepatology 2021;74:2380-94. [PMID: 34110660 DOI: 10.1002/hep.32008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
19 Basso M, Zago D, Scaggiante R, Cavinato S, Pozzetto I, Stagni C, Parisatto B, Cattelan AM, Battagin G, Sarmati L, Parisi SG. HIV tropism switch in archived DNA of HIV-HCV subjects successfully treated with direct-acting antivirals for HCV infection. Sci Rep 2021;11:9274. [PMID: 33927306 DOI: 10.1038/s41598-021-88811-6] [Reference Citation Analysis]
20 Osuch S, Laskus T, Berak H, Perlejewski K, Metzner KJ, Paciorek M, Radkowski M, Caraballo Cortés K. Decrease of T-cells exhaustion markers programmed cell death-1 and T-cell immunoglobulin and mucin domain-containing protein 3 and plasma IL-10 levels after successful treatment of chronic hepatitis C. Sci Rep 2020;10:16060. [PMID: 32994477 DOI: 10.1038/s41598-020-73137-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
21 Li J, Casey JL, Greenwald ZR, Yasseen Iii AS, Dickie M, Feld JJ, Cooper CL, Crawley AM. The 9th Canadian Symposium on Hepatitis C Virus: Advances in HCV research and treatment towards elimination. CanLivJ 2021;4:59-71. [DOI: 10.3138/canlivj-2020-0026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Phelps CC, Walker CM, Honegger JR. Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial. Viruses 2021;13:1351. [PMID: 34372558 DOI: 10.3390/v13071351] [Reference Citation Analysis]
23 Metwally NH, Abd-elmoety AS. Novel fluorinated pyrazolo[1,5-a]pyrimidines: In a way from synthesis and docking studies to biological evaluation. Journal of Molecular Structure 2022;1257:132590. [DOI: 10.1016/j.molstruc.2022.132590] [Reference Citation Analysis]
24 Perpiñán E, Pérez-Del-Pulgar S, Londoño MC, Mariño Z, Lens S, Leonel T, Bartres C, García-López M, Rodriguez-Tajes S, Forns X, Koutsoudakis G. Chronic genotype 1 hepatitis C along with cirrhosis drives a persistent imprint in virus-specific CD8+ T cells after direct-acting antiviral therapies. J Viral Hepat 2020;27:1408-18. [PMID: 32812325 DOI: 10.1111/jvh.13370] [Reference Citation Analysis]
25 Burchill MA, Salomon MP, Golden-Mason L, Wieland A, Maretti-Mira AC, Gale M Jr, Rosen HR. Single-cell transcriptomic analyses of T cells in chronic HCV-infected patients dominated by DAA-induced interferon signaling changes. PLoS Pathog 2021;17:e1009799. [PMID: 34370798 DOI: 10.1371/journal.ppat.1009799] [Reference Citation Analysis]
26 Sung PS, Shin EC. Immunological Mechanisms for Hepatocellular Carcinoma Risk after Direct-Acting Antiviral Treatment of Hepatitis C Virus Infection. J Clin Med 2021;10:E221. [PMID: 33435135 DOI: 10.3390/jcm10020221] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
27 Jansons J, Skrastina D, Kurlanda A, Petkov S, Avdoshina D, Kuzmenko Y, Krotova O, Trofimova O, Gordeychuk I, Sominskaya I, Isaguliants M. Reciprocal Inhibition of Immunogenic Performance in Mice of Two Potent DNA Immunogens Targeting HCV-Related Liver Cancer. Microorganisms 2021;9:1073. [PMID: 34067686 DOI: 10.3390/microorganisms9051073] [Reference Citation Analysis]